Browse

Welcome to another edition of Endpoints Weekly, and happy August! The summer is speeding right along, and we’ve got the latest from biopharma’s earnings-palooza this week. Let’s dive into the news.…

Novo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…